Extrahepatic portal vein thrombosis in children and adolescents: Influence of genetic thrombophilic disorders

Andrea Pietrobattista, Matteo Luciani, Juan G Abraldes, Manila Candusso, Simona Pancotti, Massimo Soldati, Lidia Monti, Giuliano Torre, Valerio Nobili

AIM: To explore the prevalence of local and genetic thrombophilic disorders as risk factors for portal vein thrombosis (PVT) in our series, the largest ever published in pediatric literature.

METHODS: We conducted a case-control study enrolling 31 children with PVT and 26 age-matched controls. All were screened for thrombophilia, including genetic disorders, protein C, protein S and homocysteine deficiencies. All coagulation parameters were studied at least 3 mo after the diagnosis of portal vein obstruction.

RESULTS: In our study we showed that most pediatric patients with PVT have local prothrombotic risk factors, which are probably the most important factors leading to PVT. However, there is a clear association between the presence of prothrombotic disorders and PVT, suggesting that these increase the risk of thrombosis in patients with local factors such as perinatal umbilical vein catheterization or sepsis.

CONCLUSION: Patients with PVT should be screened for inherited prothrombotic disorders regardless of a history of an obvious local risk factor.

Key words: Portal vein thrombosis; Children; Thrombophilic disorders; Protein C; Protein S

INTRODUCTION

Portal vein thrombosis (PVT) is a common cause of portal hypertension. To date, the pathogenesis of PVT in children still remains unexplained, yet it is the major cause of portal hypertension in children and adolescents.
Variceal bleeding due to PVT is a recognized cause of upper gastrointestinal bleeding in children in developing countries. Hereditary thrombophilias that are known to predispose to venous thrombosis and PVT include certain mutations of the prothrombin (PTHR), factor V Leiden (FV/L) or methylenetetrahydrofolate reductase (MTHFR) genes or deficiency of one of the natural anticoagulant proteins C and S.[4,5,6]

Some neonatal events such as abdominal surgery, sepsis or umbilical vein catheterization (UVC) are typically identified in patients with PVT,[7] with an incidence of thrombosis complicating UVC reported in the literature as high as 44%.[8-10] Moreover, other factors, such as dehydration, also have been suggested to play a part in PVT development.[11]

Finally, despite all efforts, the cause of the blocked portal vein remains obscure in 50% to 90% of children.[3,12] Unlike in adults, studies of thrombophilic disorders in children are scant, and to date only a few studies have evaluated the prevalence of hereditary thrombophilic disorders in children and adolescents with PVT.[12,13,14]

The aim of our study was to explore the prevalence of local and genetic thrombophilic disorders as risk factors in PVT in our series, the larger ever published.

MATERIALS AND METHODS

A 2-year prospective case-control study (December 2006 to December 2008) was carried out at Bambino Gesù Children’s Hospital in Rome, Italy. The study was conducted according to the principles of the Declaration of Helsinki, informed consent was obtained, and the authors’ institutional review board approved the study.

We enrolled two groups of subjects for the study. Group 1 included 31 (20 male) Caucasian patients with PVT; mean age, 7 yr 8 mo (range: 11 mo - 18 yr 2 mo). Group 2 comprised 26 children (15 male) free of liver disease and thrombotic events, age matched with group 1, who were inpatient in our hospital during the study. Upper endoscopy was performed in all patients of Group 1 and showed signs of portal hypertension but not always the presence of varices.

PVT was diagnosed by Doppler ultrasound scan or angiography.[14 patients underwent both these procedures and we found a very high concordance (98%)]; both procedures were performed by the same radiologist. Normal liver function tests or no other sign of liver disease was an inclusion criteria, as well as the absence of histological abnormalities on liver biopsy examination when performed.

All patients were screened for thrombophilia including genetic disorders (MTHFR C677T, FV/L, PTHR G20210A) protein C (PC), protein S (PS) and homocysteine. All coagulation parameters were studied at least 3 mo after the diagnosis of portal vein obstruction to avoid falsely low levels related to active thrombosis. Abnormal values of coagulation factors might be observed in patients with PVT due to impaired liver synthesis. Due to the lack of standards to define PC or PS deficiency in this setting, we used a ratio of these levels to prothrombin rate lower than 0.7 as a working definition for these deficits. This definition should exclude those patients with low PC and PS levels related to impaired liver synthesis, which would also affect prothrombin rate.

None of the patients were on anticoagulant or antiplatelet therapy at the time of the study. Detailed history was obtained with special emphasis on history of umbilical catheterization (50%), umbilical sepsis (6%), admission to neonatal intensive care unit (72%), severe gastroenteritis and dehydration (6%), history of thromboembolism in the patients and their family members (3%), and history of parental consanguinity (1%).

Genetic and specific analysis

Genomic DNA was isolated from white blood cells by standard procedures. A 222 bp fragment of the Factor V gene, a 165 bp fragment of the Factor II gene and a fragment of the MTHFR gene are amplified from human genomic DNA using specific primers and the amplicon is detected by fluorescence using a specific pair of probes consisting of two different oligonucleotides that hybridize to an internal sequence of the amplified fragment during the annealing phase of a PCR cycle. The same specific probes are also used to determine the genotype by performing a melting curve analysis.

PC and PS activity was measured by coagulometric assay. PC activity was measured using a specific activator extracted from southern copperhead snake venom (Agkistrodon c. contortrix; STA protein C, Roche). PS activity was determined based on the principle of activated factor V inhibition (STA protein S, Roche). Protein activity was expressed as a percentage of a reference plasma pool.

Statistical analysis

Continuous variables were compared with unpaired t-test. Categorical variables were compared with the Fisher exact test. The association between the presence of an abnormality and PVT was assessed with odds ratios and their 95% confidence intervals (CI). All analyses were performed with SPSS version 15 (Chicago, IL, USA).

RESULTS

The characteristics of the patients and controls are summarized in Table 1. In patients, the first manifestation of portal vein thrombosis occurred at a mean age of 4 year 9 mo (range: 6 mo to 16 year 2 mo). This was upper gastrointestinal (GI) bleeding in 87% of patients followed by splenomegaly in 13%. Eighty-one percent of the patients had varices at presentation, while 74% had splenomegaly. Sixty-eight percent of the patients had a history of a local prothrombotic factor (neonatal sepsis or umbilical vein catheterization). Only 1 patient with a local prothrombotic factor was present in the controls.

Congenital thrombophilic disorders

FV/L mutation was found in 2 (7%) patients and heterozygous G20210A mutation was found in 3 (10%), while
Table 1 Characteristics of the patients (mean ± SD)

|        | Controls | Patients |
|--------|----------|----------|
| Age    | 6 yr 9 mo| 7 yr 8 mo|
| Sex    | 15 males | 20 males |
| INR (%)| 1.05 ± 0.09| 1.35 ± 0.21|
| ALT (U/L)| 31.15 ± 13.83| 25.45 ± 14.71|
| AST (U/L)| 37.23 ± 11.86| 31.42 ± 11.90|
| GGT (U/L)| 16.46 ± 16.89| 17.68 ± 18.40|
| Albumin (g/dL)| 4.16 ± 0.48| 3.88 ± 0.37|
| Bil/tot (mg/dL)| 0.78 ± 0.13| 0.81 ± 0.27|
| Bil/dir (mg/dL)| 0.12 ± 0.31| 0.18 ± 0.14|
| ALP (U/L)| 404.09 ± 154.90| 515.97 ± 180.44|

INR: International normalized ratio; ALT: Aspartate aminotransferase; AST: Alanine aminotransferase; GGT: γ-glutamyl transpeptidase; Bil/tot: Bilirubin/total; Bil/dir: Bilirubin/direct; ALP: Alkaline phosphatase.

Table 2 Distribution of type and prevalence of mutations in study subjects n (%)

| Type of mutations | Control (26) | Case (31) | Total (57) |
|-------------------|--------------|-----------|------------|
| Normal            | 20 (76.9)    | 10 (32.3) | 30 (52.6)  |
| Abnormal MTHFR-C677T |              |           |            |
| Heterozygous      | 6 (23.1)     | 17 (54.8) | 23 (40.4)  |
| Homozygous        | 0 (0)        | 4 (12.9)  | 4 (7.0)    |

P = 0.001. MTHFR: Methylenetetrahydrofolate reductase.

Table 3 Frequency of inherited thrombophilic abnormalities n (%)

| Any thrombophilic factor | Control | Case | Total |
|--------------------------|---------|------|-------|
| No                       | 25 (96.2)| 21 (67.7)| 46 (80.7)|
| Yes                      | 1 (3.8)  | 10 (32.3)| 11 (19.3)|
| Total                    | 26 (100) | 31 (100)| 57 (100)|

P = 0.008 (Fisher’s exact test).

DISCUSSION

In this study we show that most patients with pediatric portal vein thrombosis have a history of a local prothrombotic factor, such as sepsis or umbilical vein catheterization, a figure much higher than that reported for adult portal vein thrombosis (around 30%). Therefore, and distinctly from adult PVT, local factors seem clearly to be the major players implicated in the development of PVT in children. However, a major finding of this study is that inherited disorders of coagulation are also frequently found in these patients (38%, as compared with 4% in controls), though most times in association with a local factor. This suggests, on one hand, that inherited thrombophilic disorders might facilitate the development of PVT thrombosis after a “local” event. On the other hand, since the presence of a thrombophilic disorder might have an impact on the management and follow-up of these patients, our data support the notion that children with PVT should be thoroughly investigated for the presence of a thrombophilic factor, even if an obvious history of a local factor is present.

The most frequent thrombophilic disorder was a deficit in naturally occurring anticoagulants (proteins C or S). It is possible, however, that the prevalence of coagulation inhibitor protein deficiency might be overestimated, since these factors might decrease due to altered liver synthesis and decreased hepatic blood flow secondary to the thrombosis, as already suggested in literature. Notably, some factors were less likely to have varices at the time of presentation (6 out of 10 patients) as compared with patients without (19 out of 21; P = 0.045).

No recurrent thrombotic events were recorded in a 24 mo long follow-up, both in patients with and without prothrombotic disorders.
studies have already shown a rise in the concentration of coagulation inhibitor proteins after a surgical correction directly bypassing the venous obstruction\textsuperscript{17,18}, confirming this hypothesis. However, even with our restrictive working definition of \textit{prot C} and \textit{S} deficit (less than 0.7 × prothrombin rate), we have found a high prevalence of these disorders, suggesting that their role is more relevant in pediatric than in adult PVT. Larger numbers with detailed family history (difficult to recruit in this setting) would be required to gain further insight into this finding.

In our population the \textit{MTHFR-C677T} polymorphism was much more frequent in patients than in controls, suggesting that it behaves as a risk factor for PVT. However, in our cohort no difference in the levels of homocysteine between controls and patients was found. Thus, this polymorphism is not always associated with high plasma levels of homocysteine\textsuperscript{19,24}, even in patients with documented thrombotic events and no other risk factor for thrombophilia. This raises the question of whether the \textit{MTHFR} gene polymorphism, without hyperhomocysteinemia, may itself contribute to thrombophilia. On the other hand, intermittent hyperhomocysteinemia may occur, which is not easily detectable even if clinically significant. In addition, the interpretation of homocysteine levels in these patients is problematic. Dietary imbalances, such as an inadequate intake of folate and vitamin B12 which are needed to break down excess homocysteine or methionine overabundance from dietary protein, may play a critical role in homocysteine metabolism\textsuperscript{21,22}.

Although the association between the \textit{MTHFR} mutation and thrombosis has not yet been fully clarified\textsuperscript{6,23,24}, anticoagulation may be indicated in patients with \textit{MTHFR} mutation (either homozygous or heterozygous, with or without hyperhomocysteinemia)\textsuperscript{25} with previous thrombotic events and other thrombotic risk factors (pregnancy, oral contraceptives, surgery, sepsis and immobilization). Therefore, our data suggest that the presence of \textit{MTHFR} mutations should be investigated in all pediatric patients with PVT. In addition, if hyperhomocysteinemia is present, therapy with folic acid and B6 and B12 vitamins should be instituted.

Another finding of this study was the lower prevalence of G1 varices in patients with prothrombotic disorders. This might be an association by chance, or could reflect that those patients with a thrombophilic factor were more likely to be diagnosed in a phase of “recent thrombosis”, when varices still have not developed. At any rate, no differences were observed in the clinical evolution of PVT between patients with genetic anomaly and those without.

In summary, most pediatric patients with PVT have local prothrombotic factors, which are probably the most important factors leading to PVT (Table 4). However, there is a clear association between the presence of pro-thrombotic disorders and PVT, suggesting that these increase the risk of thrombosis in patients with local factors such as perinatal UVC or sepsis. Patients with PVT should be screened for inherited prothrombotic disorders regardless of a history of an obvious local risk factor. Future trials should evaluate the role of prophylactic low molecular weight heparins in children requiring UVC, especially in those with a family history of thrombotic events or other thrombophilic risk factors.

**COMMENTS**

**Background**
Portal vein thrombosis (PVT) is a common cause of portal hypertension. To date, the pathogenesis of PVT in children still remains unexplained despite the fact that it is the major cause of portal hypertension in children and adolescents. Unlike in adults, studies of thrombophilic disorders in children are scant, and to date only a few studies have evaluated the prevalence of hereditary thrombo-philic disorders in children and adolescents with PVT.

**Research frontiers**
To date, many pediatric patients with PVT have local prothrombotic factors, which are probably the most important factors leading to PVT. However, there is a clear association between the presence of prothrombotic disorders and PVT, suggesting that these increase the risk of thrombosis in patients with local factors such as perinatal umbilical vein catheterization (UVC) or sepsis. Patients with PVT should be screened for inherited prothrombotic disorders regardless of a history of an obvious local risk factor. Future studies should evaluate the role of prophylactic low molecular weight heparins in children requiring UVC.

**Innovations and breakthroughs**
This series is the larger ever published so far. In this study the authors show that most patients with pediatric PVT have a history of a local prothrombotic factor, a figure much higher than that reported for adult portal vein thrombosis (around 30%). The authors suggest extending the thrombophilic screening of these different genetic mutations to better analyze this population.

**Applications**
Patients with PVT should be screened for inherited prothrombotic disorders regardless of a history of an obvious local risk factor.

**Peer review**
This is a well written and important contribution to the pediatric literature. The paper describes the wider case series of patients with these conditions and few published series are present at the moment, the data could be of interest for the readers.

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|}
\hline
\textbf{Study} & \textbf{Coagulation inhibitor protein deficit} & \textbf{Gene mutations} \\
& \textbf{PC} & \textbf{PS} & \textbf{FVL} & \textbf{MTHFR} \\
\hline
Dubuisson \textit{et al}\textsuperscript{[10]} (n = 20) & 9 (45) & 13 (65) & NP & NP \\
Utteneuther-Fischer \textit{et al}\textsuperscript{[10]} (n = 23) & NP & NP & 2 (9) & NP \\
Heller \textit{et al}\textsuperscript{[13]} (n = 24) & NP & NP & 4 (17) & 0 (1) \\
Pinto \textit{et al}\textsuperscript{[14]} (n = 14) & 6 (43) & 3 (21) & 0 (7) & 3 (21) \\
Current study (n = 31) & 4 (13) & 4 (13) & 2 (6.5) & 3 (9.7) \\
\hline
\end{tabular}
\caption{Frequency of thrombophilic disorders in children and adolescents with portal vein thrombosis \textit{n} (%)}
\end{table}
REFERENCES

1. Heller C, Schobess R, Kurnik K, Junker R, Günther G, Kreuz W, Nowak-Göttl U. Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. Br J Haematol 2000; 111: 534-539

2. Uttenreuther-Fischer MM, Vetter B, Hellmann C, Otting U, Ziemer S, Hausdorf G, Gaedicke G, Kulozik AE. Paediatric thrombo-embolism: the influence of non-genetic factors and the role of activated protein C resistance and protein C deficiency. Eur J Pediatr 1997; 156: 277-281

3. Yamada RM, Antunes MM, Cardoso SR, Servidoni Mde F, Hessel G. Umbilical vein catheterization in newborns: a family study. Arq Gastroenterol 1999; 36: 49-53

4. Nowak-Göttl U, Junker R, Kreuz W, von Eckardstein A, Kosch A, Nohe N, Schobess R, Ehrenforth S. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97: 858-862

5. Kosch A, Junker R, Kurnik K, Schobess R, Günther G, Koch H, Nowak-Göttl U. Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study. Thromb Res 2000; 99: 531-537

6. Fisher NC, Wilde JT, Roper J, Elias E. Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon? Gut 2000; 46: 534-539

7. Alvarez F, Bernard O, Brunelle F, Hadchouel P, Odièvre M, Alagille D. Portal obstruction in children. I. Clinical investigation and hemorrhage risk. J Pediatr 1983; 103: 696-702

8. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997; 78: 1-6

9. Kim JH, Lee YS, Kim SH, Lee SK, Lim MK, Kim HS. Does umbilical vein catheterization lead to portal venous thrombosis? Prospective US evaluation in 100 neonates. Radiology 2001; 219: 645-650

10. Boo NY, Wong NC, Zulkifli SS, Lye MS. Risk factors associated with umbilical vascular catheter-associated thrombosis in newborn infants. J Paediatr Child Health 1999; 35: 460-465

11. Shalmond S, Sherlock S. Obstruction to the extrahepatic portal system in childhood. Lancet 1962; 2: 63-68

12. Pinto RB, Silveira TR, Bandinelli E, Roßig L. Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders. J Pediatr Surg 2004; 39: 1356-1361

13. Dubuisson C, Boyer-Neumann C, Wolf M, Meyer D, Bernard O, Protein C, protein S and antithrombin III in children with portal vein obstruction. J Hepatol 1997; 27: 132-135

14. Sarin SK, Kumar A. Noncirrhotic portal hypertension. Clin Liver Dis 2006; 10: 627-651, x

15. Condat B, Valla D. Nonmalignant portal vein thrombosis in adults. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 505-515

16. Robson SC, Kuhn D, Kruskal J, Bird AR, Kirsch RE. Disorders of hemostasis in extrahepatic portal hypertension. Hepatology 1993; 18: 853-857

17. de Ville de Goyet J, Alberti D, Clapuyt P, Falchetti D, Rigamonti V, Bax NM, Otte JB, Sokal EM. Direct bypassing of extrahepatic portal venous obstruction in children: a new technique for combined hepatic portal revascularization and treatment of extrahepatic portal hypertension. J Pediatr Surg 1998; 33: 597-601

18. Mack CI, Superina RA, Whitington PF. Surgical restoration of portal flow corrects procoagulant and anticoagulant deficiencies associated with extrahepatic portal vein thrombosis. J Pediatr 2003; 142: 197-199

19. Kang SS, Zhou J, Wong PW, Kowalsyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-421

20. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-545

21. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9

22. Dhonukshe-Rutten RA, de Vries JH, de Bree A, van der Put N, van Staveren WA, de Groot LC. Dietary intake and status of folate and vitamin B12 and their association with homocysteine and cardiovascular disease in European populations. Eur J Clin Nutr 2009; 63: 18-30

23. Seinost G, Renner W, Brodmann M, Winkler M, Köppel H, Pilger E. C677T mutation in the methylene tetrahydrofolate reductase gene as a risk factor for venous thrombotic disease in Austrian patients. Thromb Res 2000; 100: 405-407

24. Denninger MH, Chait Y, Casadevall N, Guillin MC, Bezaud A, Erlinger S, Breier J, Dalla C. Prolonged anticoagulant treatment in young patients with portal vein thrombosis. J Gastroenterol Hepa 2010; 44: 448-451